|
|
Article: Sucampo Pharmaceuticals Releases Financial Results for 3Q 2009.
- Article from:
- Health & Beauty Close-Up
- Article date:
- November 10, 2009
CopyrightCOPYRIGHT 2009 Close-Up Media, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Sucampo Pharmaceuticals, Inc. has reported its consolidated financial results for the quarter and nine months ended September 30.
"We continue our review of Takeda's performance regarding the disappointing sales of Amitiza and possible methods to revitalize growth for the product," said Ryuji Ueno, M.D., Ph.D., Ph.D., Co-Founder, Chairman and Chief Executive Officer. "In the meantime, we continue to push forward in clinical development of Amitiza in other geographies and for other indications, we are preparing for the re-launch of Rescula for glaucoma as well as pursuing Rescula for additional indications with significant market and value potential, and we are ...